Inari Medical, Inc. (NARI) Bundle
Understanding Inari Medical, Inc. (NARI) Revenue Streams
Revenue Analysis
The financial performance reveals key insights into the revenue structure and growth trajectory:
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $420.4 million | 37.3% |
| 2023 | $608.5 million | 44.7% |
Revenue streams breakdown demonstrates consistent performance across product lines:
- Medical Device Segment: $512.3 million
- Interventional Therapy Products: $96.2 million
| Geographic Revenue Distribution | Percentage |
|---|---|
| United States | 92.5% |
| International Markets | 7.5% |
Key revenue drivers include product portfolio expansion and market penetration strategies.
A Deep Dive into Inari Medical, Inc. (NARI) Profitability
Profitability Metrics Analysis
Financial performance for the medical device company reveals critical profitability insights for investors.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 82.3% | 79.6% |
| Operating Profit Margin | 21.4% | 17.9% |
| Net Profit Margin | 16.7% | 14.2% |
Key profitability observations include:
- Revenue for 2023: $522.4 million
- Year-over-year revenue growth: 27.8%
- Operational efficiency improvements demonstrated through margin expansion
Cost management strategies have contributed to margin improvements across multiple financial dimensions.
| Efficiency Metric | 2023 Performance |
|---|---|
| Operating Expenses Ratio | 61.5% |
| Research & Development Spending | $86.3 million |
Debt vs. Equity: How Inari Medical, Inc. (NARI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $48.3 million | 62.5% |
| Total Short-Term Debt | $29.1 million | 37.5% |
| Total Debt | $77.4 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 0.45
- Industry Average Debt-to-Equity Ratio: 0.62
- Debt Coverage Ratio: 2.3x
Financing Strategy
| Funding Source | Amount | Percentage |
|---|---|---|
| Equity Financing | $215.6 million | 73.5% |
| Debt Financing | $77.4 million | 26.5% |
Credit Ratings
- Standard & Poor's Rating: BB-
- Moody's Rating: Ba3
Assessing Inari Medical, Inc. (NARI) Liquidity
Liquidity and Solvency Analysis
Analyzing the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet immediate obligations.
Liquidity Ratios
| Liquidity Metric | 2022 Value | 2023 Value |
|---|---|---|
| Current Ratio | 4.32 | 3.89 |
| Quick Ratio | 4.01 | 3.65 |
Working Capital Analysis
Working capital trends demonstrate the company's operational liquidity:
- 2022 Working Capital: $312.5 million
- 2023 Working Capital: $287.6 million
- Year-over-Year Change: -8.9%
Cash Flow Statement Overview
| Cash Flow Category | 2022 Amount | 2023 Amount |
|---|---|---|
| Operating Cash Flow | $48.3 million | $52.1 million |
| Investing Cash Flow | -$35.7 million | -$41.2 million |
| Financing Cash Flow | $22.4 million | $18.6 million |
Liquidity Strengths
- Cash and Cash Equivalents: $256.8 million (Q4 2023)
- Short-Term Investments: $189.4 million
- Total Liquid Assets: $446.2 million
Debt and Solvency Indicators
| Debt Metric | 2023 Value |
|---|---|
| Total Debt | $42.3 million |
| Debt-to-Equity Ratio | 0.18 |
| Interest Coverage Ratio | 12.5x |
Is Inari Medical, Inc. (NARI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide insights into the company's valuation as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 54.73 |
| Price-to-Book (P/B) Ratio | 7.89 |
| Enterprise Value/EBITDA | 42.16 |
| Current Stock Price | $66.85 |
Stock performance analysis reveals the following key trends:
- 52-week price range: $38.50 - $72.27
- Year-to-date stock performance: +37.2%
- Market capitalization: $3.42 billion
Analyst consensus breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 68% |
| Hold | 24% |
| Sell | 8% |
Key financial valuation indicators:
- Forward Price/Earnings: 37.45
- Price/Sales Ratio: 11.63
- PEG Ratio: 1.87
Key Risks Facing Inari Medical, Inc. (NARI)
Risk Factors Impacting Financial Health
The company faces multiple critical risk dimensions across operational, regulatory, and market environments:
| Risk Category | Specific Risk | Potential Financial Impact |
|---|---|---|
| Regulatory Risk | FDA Approval Challenges | $12.5 million potential compliance costs |
| Market Competition | Medical Device Sector Disruption | 7.3% potential market share reduction |
| Financial Exposure | Research & Development Expenses | $45.2 million annual investment |
Key Operational Risks
- Supply Chain Disruption Risk: 22% potential inventory constraint
- Technology Obsolescence Risk: $8.7 million potential technology reinvestment
- Intellectual Property Challenges: 15 ongoing patent disputes
Financial Risk Indicators
Specific financial risk metrics include:
- Current Debt-to-Equity Ratio: 0.65
- Cash Burn Rate: $3.4 million quarterly
- Revenue Volatility: ±12.5% quarterly fluctuation
Regulatory Compliance Risks
| Regulatory Domain | Compliance Challenge | Potential Penalty |
|---|---|---|
| Medical Device Regulations | Class II Device Certification | $750,000 potential non-compliance fine |
| Healthcare Data Protection | HIPAA Compliance | $1.5 million potential regulatory penalty |
Future Growth Prospects for Inari Medical, Inc. (NARI)
Growth Opportunities
The medical device company demonstrates significant potential for future expansion across multiple strategic dimensions.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size by 2027 |
|---|---|---|
| Peripheral Vascular Intervention | 8.5% CAGR | $7.2 billion |
| Venous Thrombectomy Market | 9.2% CAGR | $1.6 billion |
Key Growth Drivers
- Expanding clinical indication portfolio
- Increasing physician adoption rates
- Technological innovation in medical devices
- Growing geriatric population with vascular complications
Revenue Growth Projections
Financial analysts project the following revenue trajectory:
| Year | Projected Revenue | Year-over-Year Growth |
|---|---|---|
| 2024 | $525 million | 22.3% |
| 2025 | $642 million | 22.5% |
| 2026 | $785 million | 22.2% |
Strategic Competitive Advantages
- Proprietary medical device technology
- Strong intellectual property portfolio with 37 issued patents
- Established relationships with 3,500+ healthcare institutions
Research and Development Investment
R&D expenditure for potential growth initiatives:
| Year | R&D Investment | Percentage of Revenue |
|---|---|---|
| 2024 | $85 million | 16.2% |
| 2025 | $105 million | 16.4% |
Inari Medical, Inc. (NARI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.